Oncodesign Precision Medicine Announces a 6 Million Euros Bank Financing from Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne and Société Générale

Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces the successful signing of a financing agreement of €6 M granted by three regional banks: Caisse d'Épargne Bourgogne Franche Comté, Crédit Agricole Champagne Bourgogne and Société Générale. This financing is guaranteed by Bpifrance and P.C.G.

Oncodesign Precision Medicine, listed on Euronext Growth since November 2022, and having completed an €8 M capital increase in December 2022, of which €5 M were provided by the three co-founders, has signed a financing agreement with three regional banks. It highlights the trust, developed over time, of the OPM regional ecosystem and the key role played by geographical roots in the development of technology companies.

Over the past year, many milestones have been achieved:

• two OPM molecules have entered Phase I clinical trial in healthy volunteers: OPM-201, licensed to Servier, for Parkinson's disease, and OPM-101 for inflammatory bowel disease,
• the StarT Pancreas partnership with Servier has been launched, highlighting OPM's expertise in AI assisted identification and validation of biological targets,
• two industrial programs (Promethe for Molecular Radio Therapy, and FederAidd for the use of AI to reduce the development time of therapeutic molecules) have been launched.

This €6 M loan is equally provided by the three regional banks: Caisse d'Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne, and Société Générale, and is guaranteed by Bpifrance and P.C.G.

This financing increases OPM's cash position to €13.35 M on 03/10/2023. It enables OPM to progress as planned in the clinical development of OPM-101, specifically by continuing the MAD part of the ongoing Phase I trial in healthy volunteers and preparing Phase IIa, while continuing to develop the companies’ technologies and product portfolio.

It enables the management and the team to focus on the company's mission, which is the development of treatments for resistant and metastatic cancers, and to continue creating value within the company.

Philippe GENNE, President and Chief Executive Officer of Oncodesign Precision Medicine, said: “In a difficult general economic context for biotechs, this agreement is a real expression of faith from our loyal regional banking partners, with whom we've been working for more than 20 years. After the success of Oncodesign SA, they are following us in OPM's adventure through this innovative agreement for this sector, which goes beyond their traditional fields of activity. In particular, this financing will enable us to confidently continue the development of OPM-101 towards Phase II, without any potential time-loss due to the prevailing stock market gloom. We appreciate this expression of confidence from our regional ecosystem, which demonstrates its strong conviction and commitment to OPM's value-creation project.”